Prime Medicine (NASDAQ:PRME) Stock Jumps 11.3% – Still a Buy?

Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) shares shot up 11.3% on Wednesday. The stock traded as high as $4.09 and last traded at $4.2730. Approximately 260,194 shares were traded during mid-day trading, a decline of 92% from the average session volume of 3,383,160 shares. The stock had previously closed at $3.84.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PRME. Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a report on Monday, August 31st. Jefferies Financial Group restated a “market outperform” rating on shares of Prime Medicine in a research note on Monday, September 28th. BMO Capital Markets initiated coverage on Prime Medicine in a report on Tuesday, August 18th. They issued an “outperform” rating and a $9.00 price objective for the company. Chardan Capital reiterated a “buy” rating and set a $7.00 price target on shares of Prime Medicine in a report on Friday, September 25th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Prime Medicine in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.86.

Check Out Our Latest Analysis on PRME

Prime Medicine Price Performance

The business’s 50-day moving average price is $3.73 and its 200 day moving average price is $3.51.

Prime Medicine (NASDAQ:PRME – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Prime Medicine had a negative return on equity of 286.97% and a negative net margin of 2,497.56%. The company had revenue of $4.21 million during the quarter. On average, analysts predict that Prime Medicine, Inc. will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Prime Medicine

A number of large investors have recently bought and sold shares of PRME. Bank of America Corp DE acquired a new stake in Prime Medicine in the second quarter valued at approximately $3,621,000. BlackRock Inc. purchased a new position in Prime Medicine during the second quarter worth approximately $35,432,000. Alphabet Inc. acquired a new position in Prime Medicine in the second quarter valued at approximately $61,116,000. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Prime Medicine by 20.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,911,596 shares of the company’s stock worth $8,895,000 after purchasing an additional 498,612 shares during the last quarter. Finally, Redmile Group LLC purchased a new stake in Prime Medicine during the first quarter worth about $5,536,000. Hedge funds and other institutional investors own 70.37% of the company’s stock.

Prime Medicine Company Profile

(Get Free Report)

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

Recommended Stories

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.